PubMed:17465194 / 1763-2118 JSONTXT

{"project":"c_corpus","denotations":[{"id":"T531","span":{"begin":100,"end":108},"obj":"CHEBI:60809"},{"id":"T532","span":{"begin":146,"end":152},"obj":"UBERON:0000310"},{"id":"T533","span":{"begin":146,"end":159},"obj":"D001943"},{"id":"T534","span":{"begin":146,"end":159},"obj":"D001943"},{"id":"T536","span":{"begin":170,"end":189},"obj":"PR:000001549"},{"id":"T537","span":{"begin":170,"end":201},"obj":"CHEBI:138887"},{"id":"T539","span":{"begin":313,"end":318},"obj":"D006801"},{"id":"T540","span":{"begin":319,"end":325},"obj":"UBERON:0000310"},{"id":"T541","span":{"begin":319,"end":332},"obj":"D001943"},{"id":"T542","span":{"begin":319,"end":332},"obj":"D001943"},{"id":"T545","span":{"begin":343,"end":354},"obj":"UBERON:0002049"}],"text":"This unique model may be invaluable as a means to evaluate preclinical safety and efficacy of novel adjuvant therapies for women with metastastic breast cancer including prostanoid receptor antagonists, newly developed anti-angiogenic therapies, as well as other novel approaches for targeting and destruction of human breast tumors and their vasculature."}

{"project":"PubmedHPO","denotations":[{"id":"T32","span":{"begin":146,"end":159},"obj":"HP_0003002"},{"id":"T33","span":{"begin":146,"end":159},"obj":"HP_0100013"},{"id":"T34","span":{"begin":153,"end":159},"obj":"HP_0002664"},{"id":"T35","span":{"begin":319,"end":332},"obj":"HP_0003002"},{"id":"T36","span":{"begin":319,"end":332},"obj":"HP_0100013"},{"id":"T37","span":{"begin":326,"end":332},"obj":"HP_0002664"},{"id":"T32","span":{"begin":146,"end":159},"obj":"HP_0003002"},{"id":"T33","span":{"begin":146,"end":159},"obj":"HP_0100013"},{"id":"T34","span":{"begin":153,"end":159},"obj":"HP_0002664"},{"id":"T35","span":{"begin":319,"end":332},"obj":"HP_0003002"},{"id":"T36","span":{"begin":319,"end":332},"obj":"HP_0100013"},{"id":"T37","span":{"begin":326,"end":332},"obj":"HP_0002664"}],"text":"This unique model may be invaluable as a means to evaluate preclinical safety and efficacy of novel adjuvant therapies for women with metastastic breast cancer including prostanoid receptor antagonists, newly developed anti-angiogenic therapies, as well as other novel approaches for targeting and destruction of human breast tumors and their vasculature."}

{"project":"UseCases_ArguminSci_Discourse","denotations":[{"id":"T10","span":{"begin":0,"end":355},"obj":"DRI_Outcome"}],"text":"This unique model may be invaluable as a means to evaluate preclinical safety and efficacy of novel adjuvant therapies for women with metastastic breast cancer including prostanoid receptor antagonists, newly developed anti-angiogenic therapies, as well as other novel approaches for targeting and destruction of human breast tumors and their vasculature."}

{"project":"PubMed_ArguminSci","denotations":[{"id":"T8","span":{"begin":0,"end":355},"obj":"DRI_Outcome"}],"text":"This unique model may be invaluable as a means to evaluate preclinical safety and efficacy of novel adjuvant therapies for women with metastastic breast cancer including prostanoid receptor antagonists, newly developed anti-angiogenic therapies, as well as other novel approaches for targeting and destruction of human breast tumors and their vasculature."}